- Home
- FA vs DYN Comparison
FA vs DYN Comparison
Compare FA & DYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FA
- DYN
- Stock Information
- Founded
- FA 2003
- DYN 1984
- Country
- FA United States
- DYN United States
- Employees
- FA 10000
- DYN N/A
- Industry
- FA Business Services
- DYN Medicinal Chemicals and Botanical Products
- Sector
- FA Consumer Discretionary
- DYN Health Care
- Exchange
- FA Nasdaq
- DYN Nasdaq
- Market Cap
- FA 2.2B
- DYN 1.9B
- IPO Year
- FA 2021
- DYN 2020
- Fundamental
- Price
- FA $14.14
- DYN $18.32
- Analyst Decision
- FA Buy
- DYN Strong Buy
- Analyst Count
- FA 4
- DYN 14
- Target Price
- FA $20.67
- DYN $34.93
- AVG Volume (30 Days)
- FA 784.0K
- DYN 2.9M
- Earning Date
- FA 11-06-2025
- DYN 11-05-2025
- Dividend Yield
- FA N/A
- DYN N/A
- EPS Growth
- FA N/A
- DYN N/A
- EPS
- FA N/A
- DYN N/A
- Revenue
- FA $1,251,464,000.00
- DYN N/A
- Revenue This Year
- FA $84.14
- DYN N/A
- Revenue Next Year
- FA $5.93
- DYN N/A
- P/E Ratio
- FA N/A
- DYN N/A
- Revenue Growth
- FA 65.34
- DYN N/A
- 52 Week Low
- FA $12.25
- DYN $6.36
- 52 Week High
- FA $20.79
- DYN $35.68
- Technical
- Relative Strength Index (RSI)
- FA 49.60
- DYN 50.24
- Support Level
- FA $12.25
- DYN $23.05
- Resistance Level
- FA $14.75
- DYN $24.25
- Average True Range (ATR)
- FA 0.55
- DYN 1.46
- MACD
- FA -0.01
- DYN -0.14
- Stochastic Oscillator
- FA 70.40
- DYN 28.22
About FA First Advantage Corporation
First Advantage Corp is a provider of global software and data in the Human Resources technology industry. The company leverages proprietary technology and AI across its platforms, data, and APIs to deliver comprehensive background screening, digital identity, and verification solutions driven by innovation, automation, and customer success. Its reportable segments are First Advantage Americas, First Advantage International, and Sterling. Maximum revenue is generated from the First Advantage Americas segment. The group serves customers in over 200 countries and territories, modernising hiring and onboarding on a global scale.
About DYN Dyne Therapeutics Inc.
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease are seeking to treat, a linker, and an antigen-binding fragment, that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.